Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway

Journal of Pathology

Volumn 234, Issue 2, 2014, Pages 152-163

  Fusella, Federica ^a   Ferretti, Roberta ^a,d   Recupero, Daniele ^b   Rocca, Stefania ^a   Di Savino, Augusta ^a   Tornillo, Giusy ^a,e   Silengo, Lorenzo ^a   Turco, Emilia ^a   Cabodi, Sara ^a   Provero, Paolo ^a   Pandolfi, Pier Paolo ^a,c   Sapino, Anna ^b   Tarone, Guido ^a   Brancaccio, Mara ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Chemoresistance; Morgana; PTEN; ROCK

Indexed keywords

MORGANA PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; ROCK I KINASE; ROCK II KINASE; UBIQUITIN; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; CARRIER PROTEIN; CHP 1 PROTEIN, MOUSE; CHP PROTEIN, HUMAN; CHP-1 PROTEIN, MOUSE; PTEN PROTEIN, HUMAN; PTEN PROTEIN, MOUSE; RHO KINASE;

3T3 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CENTROSOME; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MITOSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; CHEMORESISTANCE; METABOLISM; MORGANA; PATHOLOGY; PHYSIOLOGY; PTEN; ROCK;

BREAST CANCER; CHEMORESISTANCE; MORGANA; PTEN; ROCK;

ANIMALS; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CARRIER PROTEINS; CENTROSOME; DOWN-REGULATION; FEMALE; HUMANS; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84907961850     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4341     Document Type: Article

References (34)

1. Brancaccio M, Menini N, Bongioanni D, et al. Chp-1 and melusin, two CHORD containing proteins in vertebrates. FEBS Lett 2003; 551: 47-52.
2. MichowskiW, Ferretti R,Wisniewska MB, et al. Morgana/CHP-1 is a novel chaperone able to protect cells from stress. Biochim Biophys Acta 2010; 1803: 1043-1049.
3. Hahn JS. Regulation of Nod1 by Hsp90 chaperone complex. FEBS Lett 2005; 579: 4513-4519
4. Ferretti R, Palumbo V, Di Savino A, et al. Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis. Dev Cell 2010; 18: 486-495.
5. Hanashiro K, Brancaccio M, Fukasawa K. Activated ROCK II by-passes the requirement of the CDK2 activity for centrosome duplication and amplification. Oncogene 2011; 30: 2188-2197.
6. Shirasu K, Lahaye T, Tan MW, et al. A novel class of eukaryotic zinc-binding proteins is required for disease resistance signaling in barley and development in C. elegans. Cell 1999; 99: 355-366.
7. Ferretti R, Sbroggio M, Di Savino A, et al. Morgana and melusin: two fairies chaperoning signal transduction. Cell Cycle 2011; 10: 3678-3683.
8. Fukasawa K. Oncogenes and tumour suppressors take on centrosomes. Nature Rev Cancer 2007; 7: 911-924.
9. Ganem NJ, Godinho SA, Pellman D. Amechanism linking extra centrosomes to chromosomal instability. Nature 2009; 460: 278-282.
10. Crasta K, Ganem NJ, Dagher R, et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 2012; 482: 53-58.
11. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
12. SbroggioM, BerteroA,Velasco S, et al. ERK1/2 activation in heart is controlled by melusin, focal adhesion kinase and the scaffold protein IQGAP1. J Cell Sci 2011; 124: 3515-3524.
13. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
14. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-1270.
15. Cicalese A, Bonizzi G, Pasi CE, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009; 138: 1083-1095.
16. Hafsi S, Pezzino FM, Candido S, et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol 2012; 40: 639-644.
17. Li Z, Dong X, Wang Z, et al. Regulation of PTEN by Rho small GTPases. Nature Cell Biol 2005; 7: 399-404.
18. Vemula S, Shi J, Hanneman P, et al. ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood 2010; 115: 1785-1796.
19. Chang J, Xie M, Shah VR, et al. Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci U S A 2006; 103: 14495-14500.
20. Morgan-Fisher M, Wewer UM, Yoneda A. Regulation of ROCK activity in cancer. J Histochem Cytochem 2013; 61: 185-198.
21. Perez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007; 13: 3577-3584.
22. Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 2014; 232: 142-150.
23. Coleman ML, Sahai EA, Yeo M, et al. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nature Cell Biol 2001; 3: 339-345.
24. Sebbagh M, Renvoize C, Hamelin J, et al. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nature Cell Biol 2001; 3: 346-352.
25. Shi J, Wei L. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp (Warsz) 2007; 55: 61-75.
26. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nature Rev Mol Cell Biol 2012; 13: 283-296.
27. Marty B, Maire V, Gravier E, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008; 10: R101.
28. Lopez-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010; 126: 1121-1131.
29. Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012; 2012: 217185.
30. Iqbal J, Thike AA, Cheok PY, et al. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer. Histopathology 2012; 61: 652-659.
31. Laios A, O'Toole SA, Flavin R, et al. An integrative model for recurrence in ovarian cancer. Mol Cancer 2008; 7: 8.
32. Di Fiore PP. Playing both sides: nucleophosmin between tumor suppression and oncogenesis. J Cell Biol 2008; 182: 7-9.
33. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147-153.
34. Hollestelle A, Elstrodt F, Nagel JH, et al. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 2007; 5: 195-201.